portfolio 1 16 james winslow

2

Portfolio | Jim Winslow

> Infographics: Charts

Percent Immunized0 10 20 30 40 50 60 70 80

HPV 1+

MCV

Tdap

TD/Tdap

2006

2007

2008

Source: National Foundation for Iinfectious Diseases

Data derived from Centers for Disease Control and Prevention (CDC). Estimated Vaccine Coverage With Selected Vaccines Among Adolescents Aged 13-17 Years, by State and Selected Local Areas – National Immunization Survey-Teen, United States, 2006, 2007, 2008.Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2006, 2007, 2008.

60.1

10.8

30.4

40.8

11.7

32.4

41.8

25.1

17.9

72.3

72.2

19.3

Figure 1

Vaccination Rates in Adolescents 13-17 Years of Age, U.S.—2006-08

2008 Rates for1 dose and 3 doses

1 Dose

3≥ Doses

Group NHANES

1976-1980

2003-2004

Adultsaged 20-74 years

Adolescentsaged 12-19 years

Childrenaged 6-11 years

Children 2-5 years

15.0%

5.0%

6.5%

17.4%

18.8%

13.9%

5.0%

32.9%

Prevalence of Obesity* 1976-1980 to 2003-2004

Composition of HFCS

Composition of Sucrose

HFCS in Beverages

HFCS in Baked Goods

Fructose 50%

Glucose50%

Fructose 55%

Polysaccharides(glucose polymers)1-3%

Polysaccharides(glucose polymers)4-6%

Glucose42-44%

Fructose 42%

Glucose52-54%

* Using 95th percentile of Body Mass index for children and adolescents 2-19 years of age.

0

10

20

30

40

50

20102009200820072006200520042003

Newspaper Ad Revenues Versus Google Ad Revenues

Bill

ion

s

Source: Newspaper Association of America.http://www.naa.org/Trends-and-Numbers/Advertising-Expenditures/Annual-All-Categories.aspxGoogle ad reveune from Yahoo Finance

$46.2b$49.3b

53.0% Drop in Expenditures

287.7% Rise in Revenues

$25.9b

$10.5b

$36.5b

Total Newspaper Advertising Expenditures, Print & Online

Google Ad Revenue

1.4b

> Charts and graphics created in Illustrator

3


> Infographics: Charts

30.4% 32.4%41.8%40.8%

80%

2007

Healthy People 2010 Goal

Whooping Cough Meningitis

Whooping Cough & Meningitis Vaccination Rates Among Teens Are Increasing But Still Fall Short of Healthy People 2010 Goals of 80%

Free and low-cost vaccine available through national Vacciones for Children program; visit your local health department to learn more

2007 20082008

Vaccination Rates for Teens 13-17 Years Old

Source: Centers for Disease Control and Prevention

> Charts and graphics created in Illustrator

A GfK Roper telephone survey of 1005 adults aged 18 and older was completed, with 663 among the target subgroup of adults aged 18-64.The margin of error for this study is +/- 3 percentage points for total sample and is higher for subgroups.

This survey was sponsored by Sanofi Pasteur, the vaccines division of Sanofi. For more information visit www.fluzone.com.

Spreading the Flu to Family and Friends ScaresMore Adults than Common Halloween Frights

67%39%

The Dark Movies Black WidowSpiders

Spreading the Fluto Loved Ones

9% 24%

Yet, Few Take Action!

Even though everyone 6 months of age and older should be vaccinated1

3 in 5 adults remain unvaccinated, leaving many vulnerable to influenza

Talk to your health care provider or pharmacist about flu vaccine options.

Reference:1. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(33):1128-1132.

COM10698

Meningitis

80%

0%

20%

40%

60%

Healthy People 2010 Goal

Whooping Cough

Whooping Cough & Meningitis Vaccination Rates Among Teens Are Increasing But Still Fall Short of Healthy People 2010 Goals of 80%

Free and low-cost vaccine available through national Vaccines for Children program; visit your local health department to learn more

Vaccination Rates for Teens 13-17 Years Old

Source: Centers for Disease Control and Prevention

32.4%

41.8%

20082007

30.4%

40.8%

2007 2008

Males immune to diphtheria

Females immune to diptheria

6-11 12-19 20-19 30-39 40-49 50-59 60-69 Over 70

Immunity to Diptheria Declines With Age

Imm

unity

%

100

80

60

40

20

0

Age

0

10

20

30

40

50

60

70

80

90

Farming or gardening

31%

At home or indoors

45%

Outdoor activities

23%

Auto Accident 1%

Source: CDC

Sources of Tetanus Injuries

...protection is lowest in older AmericansWhile most Americans are protected against diphtheria and tetanus...

Imm

unity

%

Protection Against Diphtheria and Tetanus

Full protection against diphtheria

Full protection against diphtheriaand tetanus

Full protection against diphtheriaand tetanus

Full protection against tetanus

6 years of age and older 6-11 years of age Over 70 years of age

60.5%

91%

72.3%

31%

2 in 3 say their biggest fear regarding influenza is spreading it to friends and family

Increases Vaccination Rates!

Adults 18 to 64

Fluzone Intradermal vaccine is a safe and effective way to help prevent influenza. Redness, firmness, swelling, and itching at the injection site occur more frequently with Fluzone Intradermal vaccine than Fluzone vaccine. Other common side effects include pain, headache, fatigue, and muscle aches.

A telephone survey of 1005 adults aged 18 and older was completed, with 663 among the target subgroup of adults aged 18-64. The margin of error for this study is +/- 3 percentage points for total sample and is higher for subgroups.

To find out where to get Fluzone Intradermal, visit Fluzone.com, or talk to your health care provider or pharmacist for more information

Smaller Needle90%

Alternative technologies, such as Fluzone Intradermal vaccine, which has a 90% smaller needle, provides new strategy

Are You Spreading The Flu?

Yet, 3 in 5 adults remain unprotected against the flu

About 5 to 20 percent of the population get influenza annually1

Reference:

1. Centers for Disease Control and Prevention (CDC). Seasonal influenza (flu) – q&a: seasonal influenza (flu): the disease. http://www.cdc.gov/flu/about/qa/disease.htm. Accessed June 25, 2012.

4


> Infographics: Timelines

Influenza Vaccine Timeline Timing of egg-based and cell culture production

4Determines amount/ yield of virus strains 4Purity and potency tested4The 3 strains are blended into 1 vaccine by the manufacturer4FDA licenses the vaccine

4Vaccine is filled into vials and syringes4Vaccine is packaged for distribution4Kept in cold storage to ensure potency

4Shipping of influenza vaccine begins

Production begins

Virus selection4FDA advisory panel selects 3 strains4CDC provides new strains of the seed virus to the FDA4FDA distributes the 3 seed viruses to manufacturers

January February March April May June July August September

4Seed virus resorted with reference virus*

4Seed virus is injected into fertilized chicken eggs

4Virus multiplies in incubated eggs

4Allantoic fluid (egg white) is removed, virus is

harvested

4Chemical treatment applied – ensures virus is

inactivated

4Multiple purifications throughout process

*Resorting improves virus yield in egg-based production but has not been shown to affect yield in cell culture production

FDA tests to confirm production

Filling/Packaging

Egg-Based Production

Cell Culture Production FDA Testing

FDA Testing Packaging Shipping

ShippingPackaging4Cells grown in increasingly large vessels

4Flasks

4Bottles

4Small, medium, large bioreactors

4Mature cells inoculated with seed virus

4Virus multiples in cells

4Chemical treatment applied–ensures

virus is inactivated

4Multiple purifications throughout process

Theoretically, vaccine could be available up to 3 weeks earlier using cell culture methods, however lower yields compared with egg-based production may affect vaccine supply

> Timelines created in Illustrator

Pre-vaccine EraEstimated 12,000–20,000 cases a year in U.S.: 3-6% fatal

1889 1920 1929 1933 1930-40 1950-70 1970s Early 1980s 1980s 1985 1987 1991 1995 1996-00 Present

[1929] Researchers create first bacterial polysaccharide conjugate vaccine*. Discovery will serve as basis for development of first conjugate vaccine for Haemophilus influenzae type b (Hib) 58 years later.* A conjugate vaccine is a vaccine that has been “joined” to a protein in order to improve the body’s response to invading substances such as bacteria.

[1930-40] Pioneering research by Dr. Margaret Pittman of the National Institutes of Health leads to greater understanding of infections caused by Hib and forms the basis for the first effective treatments for invasive Hib disease. Dr. Pittman observes that H. influenzae type b accounts for nearly all strains that cause invasive disease.

[1970s] Research yields the first vaccine for Hib, however vaccine effectiveness is limited in children under 2 years of age.

[1980s] Researchers develop and test conjugate vaccine for Hib.

Post-vaccine EraCases drop to an average of 68 a year in U.S.

Haemophilus influenzaeHibdisease.com

[1985] First Hib vaccine licensed. Vaccine is not effective in children under 18 months of age.

■ 1889 Discovery of Hib bacteria

■ 1929 First vaccine prototype created

■ 1930-1940 First effective antibiotic treatments

■ 1980 Estimated 20,000 cases a year

■ 1987 First conjugate vaccine licensed

A Vaccine-preventable Disease

[1920] Scientists give name Haemophilus (Latin for “blood loving”) influenzae to the organism to show its relationship to flu and blood diseases.

[1933 ] Researchers establish that flu is a virus and that H. influenzae is the result of a secondary infection, not the cause of flu as earlier believed. Researchers also observe that disease is most common in children under 5 years of age. Later research will confirm the close relationship between age and Hib disease. Occurrence of the disease peaks at 6-7 months of age. Cases after 5 years of age are uncommon.

[1950-70] Advances in antibiotics improve treatment, but fail to make progress in eliminating Hib disease, prompting the development and licensing of vaccines over the next two decades. Hib continues to be the most common cause of bacterial meningitis in children under 5 years of age with approximately 12,000 cases a year. Bacterial meningitis is an infection of the spinal fluid and tissues that surround the brain and spinal cord. Of those, 3-6% of cases result in death. Up to 30% of survivors suffer from neurological disorders including hearing loss, seizures, and mental retardation.

[Early 1980s] Annual cases in U.S. estimated to be about 20,000, primarily among children younger than 5 years of age.

[1991] Routine immunization with Hib conjugate vaccines recommended by American Academy of Pediatrics, Committee on Infectious Diseases and the U.S. Centers for Disease Control and Prevention (CDC).

[1889] Haemophilus influenzae (H. influenzae) bacterium isolated during the 1889 influenza (flu) pandemic by Dr. Richard Pfeiffer. Bacterium is believed at the time to be a cause of flu.

[1995] CDC study finds that immunization with conjugate Hib vaccines has drastically changed the epidemiology of bacterial meningitis, making it a disease of adults rather than infants and young children. Median age of cases rises from 15 months in 1986 to 25 years in 1995.

[Present] Hib cases in the U.S. have declined by more than 99% since the introduction of vaccines. Three Hib vaccines are licensed for use in infants as young as 6 weeks of age. All three have been shown to be highly effective.

Despite the amazing success of Hib vaccination in the U.S., Hib disease remains a threat. Without high immunization rates, Hib could still strike at the same level (one in 200 children with a death rate of 5%) as before vaccines were available in the U.S.

Worldwide, Hib remains a major source of deaths and disabilities in children, with an estimated three million cases of serious disease and as many as 700,000 deaths a year.

[1987] First conjugate vaccine licensed. Technology used to create conjugate vaccines for Hib serves as a model for vaccines developed in the next decade.

Photo courtesy of CDC

[1996-2000] Hib cases fall to an average of 68 cases per year in U.S.

Learn More

> 4 color posters for print. Layout and design: InDesign,; graphics created in Illustrator and Photoshop

l The origin of the word

cancer is credited to the Greek physician Hippocrates (460-370 B.C.), considered the “Father of Medicine.” Hippocrates used the terms carcinos and carcinoma to describe non-ulcer forming and ulcer-forming tumors

Joseph Claude Anthelm l Recamier was the first

to recognise cancer metastasis

l In 1953, James Watson and Frances Crick unleashed a tidal wave of new discoveries with their model of DNA’s structure. Cancer researchers contributed much of this new information as they continued to search for “magic bullets”

l The effects of cisplatin, a platinum based compound, on cell division is discovered and investigated by Barnett Rosenberg at Michigan State University. Platinum based compounds are now an important part of chemotherapy

l A major breakthrough - James Holland, Emil Freireich and Emil Frei hypothesised that cancer chemotherapies could be used in combination, each with a different mechanism of action. This quickly gained widespread acceptance among cancer clinicians

l Emil Frei and colleagues first demonstrate that chemotherapy given after surgical removal of a tumour (adjuvant therapy) improves cure

l EUROPA DONNA, The European Breast Cancer Coalition founded

l Xeloda is the first oral 5-FU chemotherapy approved by the FDA as monotherapy for the treatment of advanced breast cancer

l Xeloda is approved in the US and Europe for the treatment of advanced colorectal cancer

l Researchers announce a new screening test for colon cancer that detects specific genetic abnormalities in stool samples of up to 70% of patients with colon cancer

l Researchers find that a simple blood test helps predict colon cancer

l Europacolon, the first Pan-European Advocacy group dedicated to colorectal cancer is founded

l Xeloda is approved in the US and EU as monotherapy for the post-surgery treatment of Dukes’ C (Stage III) Colon Cancer

Xeloda is approved in l

Japan for the post-surgery treatment of Dukes’ C (Stage III)

Colon Cancer

Xeloda is approved in lEurope in combination

with platinum-based chemotherapy for

first-line use in patients with advanced

stomach cancer

In Europe, Xeloda and Avastin lare approved in combination

with any chemotherapy in all lines of treatment for

advanced colorectal cancer.Patients can now benefit from

these innovative treatments

Study showing lXeloda’s potential as a pre-operative

(neo-adjuvant) treatment for early

breast cancer

Two pharmacologists lLouise Goodman

and Alfred Gilman use nitrogen mustard

to treat a patient with Non-Hodgkin’s

lymphoma and demonstrate for

the first time that chemotherapy can

induce tumour regression

Xeloda Era

Chemotherapy Through the Years: Celebrating 10 Years of Xeloda

20022001 20041998199319721963 19651942 1953460 BC 2005 2007 2008

l Xeloda is approved in the US in combination with docetaxel for the treatment of advanced breast cancer

l Xeloda is approved in Europe in combination with docetaxel for the treatment of advanced breast cancer

2003

l Researchers in Cambridge show that the lifetime risk of developing breast cancer is doubled in most women who carry a faulty CHEK2 (checkpoint kinase, 2) gene

Mark Skolnik and co-workers l

discover the BRCA1 (breast cancer,1) gene, while Mike

Stratton and co-workers discover the BRCA2 gene.

British epidemiologists predict that a woman with a mutation in BRCA1 has approximately 85 percent

chance of developing breast cancer if she lives beyond

the age of 70

1994/5

l William Halstead develops the radical mastectomy believing that cancer can be cured by surgically removing the tumour and surrounding tissues

1829

Pre-Xeloda1882

Roche develops l

5-fluorouracil (5-FU), a

chemotherapy drug used to treat many

cancers

l Xeloda reaches blockbuster status and has now treated in excess of 1.5 million patients

l Anticipatedcompletion of study showing efficacy of Xeloda with or without Avastin in early stage colon cancer

1958

Xeloda: Advances in Gastrointestinal Cancer Treatment

Xeloda: Advances in Breast Cancer Treatment

l Xeloda approved in Japan for the treatment of patients with inoperable or recurrent breast cancer

More to Come

l Data showing Xeloda efficacy as a post-operative (adjuvant) treatment of breast cancer expected

5


> Posters

Vaccines have saved millions of lives, mainly babies and children.

True. Before vaccines were available to protect us, millions of children and adults in the United States lost their lives or were permanently harmed due to deadly infections like polio, whooping cough (pertussis) and flu (influenza). But now, many of these diseases have virtually disappeared, thanks to vaccines! However, if parents don’t continue to vaccinate children, many of these diseases can, and will, return.

Vaccines prevent more than a dozen potentially deadly diseases in children by age 2.

True. By the time children reach age 2, today’s vaccines can protect against serious diseases including chickenpox (varicella), whooping cough, diphtheria, tetanus, polio, measles, mumps, rubella, Hib disease, hepatitis A & B, rotavirus, pneumococcal disease (pneumonia, blood infections and meningitis) and flu. That’s 14 diseases your child is protected against with vaccines!

Because of vaccines, some diseases no longer occur in the United States.

True. Since vaccines for polio and smallpox came into everyday use, neither disease occurs in the United States. In fact, vaccination efforts have been so effective that smallpox doesn’t occur anywhere in the world!

Vaccination is one of the top public health achievements over the last 100 years.

True. Vaccination is considered to be one of the “Ten Great Public Health Achievements in the 20th Century.”* In fact, vaccination is at the top of the list! Why? Because vaccines protect children against many diseases that were feared generations ago. (*According to the Centers for Disease Control and Prevention)

You should talk to your health care provider about how on-time vaccination can help protect your baby.

True. Your health care provider has played a big role in helping to protect children through vaccination and can answer any questions you have. By working with your provider, you can help ensure that your child is healthy and fully protected!

TWO FOR 2 Adherence Campaign

rue Or alse?T F

What’s also true is that vaccination is one of the easiest ways to guarantee that your child remains healthy and is protected between

birth and 2 years of age—when they need it the most!

Este anuncio es posible gracias al apoyo de Sanofi Pasteur Inc.

Programa de Vacunas para Niños(Vaccines for Children)

Pregunte a su proveedor de atención médica o al departamento de salud local cómo acceder a vacunas gratis o a bajo costo para niños y adolescentes.

n Los niños y los adolescentes corren el riesgo de contraer enfermedades potencialmente mortales como la gripe, la meningitis, la tos convulsa y el virus del papiloma humano (human papillomavirus, HPV).

n Sólo alrededor de la mitad de los adolescentes hispanos en los EE. UU. reciben la vacunación contra estas graves enfermedades infecciosas.

¡Ayude a proteger la salud de sus hijos vacunándolos!

Vacunas gratis o a bajocosto para niños y adolescentes

Busque su departamento de salud local mediante

el código postal en www.naccho.org/widget

CHAUNCEY BILLUPS SAYS…“KEEP TEENS IN THE GAME!”Defend Teen HealthGet Teens Vaccinated

(c) 2

010

NB

A E

nter

tain

men

t. P

hoto

by

Noa

h G

raha

m (N

BA

E/G

etty

Imag

es).

All

right

s re

serv

ed.

Visit VACCINESFORTEENS.NET for more information

Teens may be at risk for serious and potentially life-threatening diseases like meningococcal meningitis, whooping cough, and the flu.

Vaccination is a safe and effective way to help protect them.

Just like on the basketball court, the best offense is a good defense.

Almost Everything You Ever Wanted to Know About

A Short Course on How Vaccines Work





Sponsored by Fondation Mérieux and the AIDS Vaccine Advocacy CoalitionSupport provided by sanofi pasteur

Sunday, 13 August 10:15-12:15Level 200 Skills Building Room 8

n Where is the AIDS vaccine?

n Cellular responses, antibody responses…what do they really mean?

n What’s being studied today, and what’s in the pipeline for tomorrow?

The program is open to all conference attendeesBreakfast will be served

6


> Postcards

Continuing Education (CE)

Asthma is the most common chronic medical condition among children, af-fecting more than six million children younger than 18 years of age in the U.S.

Despite longstanding CDC recom-mendations, influenza vaccination rates among children with asthma remain seriously low. Children with chronic medical conditions, including asthma, are at an increased risk for influenza-re-lated complications (e.g., pneumonia, increased outpatient visits and antibiotic prescriptions).

PNPs, NPs and nurses are key influencers in a pediatrician’s practice and are often responsible for educating patients and their parents about the importance of immunization and organizing in-practice vaccination programs.

While providers agree on the severity of influenza among children with asthma, many practices do not have an infrastruc-ture in place to help identify, recall and annually immunize these children.

The CE program will feature strategies and models implemented in a variety of practice settings that have been successful in maximizing pediatric asthma influenza

immunization rates. It is designed to help PNPs, NPs and nurses have a significant positive impact on influenza vaccination rates among their pediatric patients, par-ticularly for those with chronic medical conditions, such as asthma.

Target Audience n Pediatric nurse practitioners n Nurse practitioners n Nurses

Learning ObjectivesAt the conclusion of this program, at-tendees should be able to:

n Identify the CDC influenza immunization recommendations for children with asthma

nDiscuss the impact of low immuni-zation rates among pediatric asthma patients

n Address the burden of influenza disease in children with asthma

n Describe the safety and efficacy of influenza vaccination among this high-risk population

n Decide which strategies may be used to increase influenza vaccination rates in their practices

Coo

ney/

Wat

ers G

roup

141

Fifth

Ave

nue,

9th F

loor

New

Yor

k, N

Y 10

010

This

pro

gram

has

bee

n ap

prov

ed fo

r

2.4

NA

PN

AP

con

tact

hou

rs o

f whi

ch

1.2

are

phar

mac

olog

y co

nten

t.

Accr

edita

tion

Stat

emen

t: S

anofi

pas

teur

has

bee

n gi

ven

mee

ting

spa

ce t

o pr

ovid

e an

edu

cati

onal

off

erin

g du

ring

NA

PN

AP

’s A

nnua

l Con

fere

nce.

N

AP

NA

P’s

app

rova

l of

mee

ting

spa

ce o

r co

ntin

uing

edu

cati

on c

redi

t do

es n

ot im

ply

prod

uct

endo

rsem

ent.

CHILDREN WITH ASTHMA AND INFLUENZAPractice Models for Improving Influenza Immunization Rates Among Children with Asthma

You are invited to attend a NAPNAP contact hour satellite symposium

Friday, March 31, 2006 Dinner and Registration: 6:30 p.m.Presentations: 7:00 p.m.Marriott Wardman Park Hotel, Salon 1Washington, D.C.

Reg

iste

r N

ow!

E-m

ail:

rsvp

@as

thm

aflu.

com

Ph

one:

212

-886

-226

5

Made possible by support from sanofi pasteur

Symposium Overview

To learn more, visit: www.abbottglobalcare.org

Using Innovative Programs and Groundbreaking Technologies to Improve Health

An AMPATH counselor, using a PDA and a GPS device, provides home-based HIV counseling and testing, TB screening, Malaria bed nets and de-worming medication as part of an Abbott Fund pilot project in Turbo, Western Kenya.

Picturing HopeThrough Their EyesPhoto: Revathi, Age 14

The Asia Society Invites You to a Special Event and Exhibition in Commemoration of World AIDS Day

Picturing HopeThrough Their EyesThis display of photographs, taken by children in India, provides a close look at how the global HIV/AIDS epidemic is shaping everyday lives. The images are selected from Picturing Hope, a program dedicated to providing children impacted by HIV/AIDS with resources to explore their feelings, strengthen their sense of self, and find a voice with which to tell their stories.

Tuesday, November 29, 2005Opening Reception 6:30–8:30 p.m.Remarks and program at 7:00 p.m.

Complimentary Admission, RSVP Requested. Limited Space Available.Asia Society and Museum, 725 Park Avenue at 70th street, New York City

To accept this invitation, please call the Asia Society Box office at 212-517-ASIA, or email: [email protected]

Made possible by an unrestricted grant from the Abbott Fund

Watch Videos Featuring Tips From:

Shelley K., Epilepsy Advocate, mother and caregiver of a college-bound 21-year-old daughter diagnosed with epilepsy at age six. and who is

Heather E., Epilepsy Advocate, diagnosed with epilepsy while in college, married for 13 years, raising two young children, and working toward an advanced degree in the legal field.

Blanca Vazquez, MD, provides perspective on how epilepsy uniquely affects women. Dr. Vazquez is an epilepsy specialist and assistant professor at the NYU School of Medicine.

Women Succeeding with Epilepsy

To watch, go to EpilepsyAdvocate.com or HealthyWomen.org

Succeeding with Epilepsy

Beth Battaglino, RN, Executive Director, HealthyWomen

Blanca Vazquez, MD, NYU School of Medicine

Heather E., Epilepsy Advocate Shelley K., Epilepsy Advocate

Hear personal stories from real women who have faced and overcome the unique challenges posed by epilepsy

This symposium is made possible by an unrestricted educational grant to the National Meningitis Association from GlaxoSmithKline.

The Role Nurse Practitioners Play in Preventing Meningococcal Disease

To the National Meningitis Association’s Non-CE Educational Symposium:

Speakers will include:Mary Beth Koslap-Petraco, DNP, CPNP, Coordinator Child Health, Suffolk County Department of Health ServicesPaul J. Lee, MD, Pediatric Infectious Diseases and International Adoption Program, Winthrop-University HospitalLynn Bozof, President, National Meningitis Association

At NAPNAP’s 31st Annual Conference on Pediatric Health Care

Date: April 17, 2010 | Time: 7:00AM – 8:30AM Location: Grand Ballroom AB

Breakfast will be served

To register, please visit http://www.nmaus.org/panel/events/ or call, 212-886-2214.

You’re Invited!

Availability is limited to the first 250 registrants.

Thursday, March 22, 2007 6:00–9:30 p.m. At the NAPNAP 28th Annual ConterenceDinner and Registration: 6:00 p.m.Presentations: 7:00 p.m.Disney’s Coronado Springs Resort, Fiesta 6Lake Buena Vista, FL

TWO FOR 2 Adherence Campaign

Made possible by support from sanofi pasteur

Strategies to Facilitate Parent-Provider Dialogue to Encourage On-Time Vaccination by Age 2

REGISTER NOW!

Pre-registration now availableOn-site registration available

E-mail: [email protected]: (212) 886-2250

This program is pending approval by the National Association of Pediatric Nurse Practitioners (NAPNAP) for 1.2 NAPNAP contact hours.

7


> Brochures/Programs

XV International AIDS Conference Bangkok, Thailand; July 11-16, 2004

CD-ROM Abstracts

Ten Years of Mobilizing and Strengthening Community Responses to HIV/AIDS in Burkina Faso The experience of IPC and the International HIV/AIDS Alliance, results and les-sons learnedLead Author: B. Millogo – IHAA

Scaling up Community Mobilization and Responses to HIV/AIDS Through Secondary Mobilization of CBOs The experience of IPC/BF in Burkina Faso Lead Author: D. Bassonon – IHAA

Role and Place of Social Welfare Organizations in the Emer-gence of Community Responses to HIV/AIDS in Burkina FasoThe case of Association Solidarité et Entraide Mutuelle au Sahel (SEMUS); Solidarity and Mutual Help in the SahelLead Author: M. Yameogo – IHAA

Institutions, Communities and the Continuum of Care for Children Affected by AIDSLead Author: J. Parker – Development Alternatives Inc.

Building an AIDS-in-the-Workplace Program in Developing Country Offices Lessons learned from Abbott LaboratoriesLead Author: J. Richardson – Abbott Laboratories Fund

Powerful Techniques to Reduce Stigma and Discrimination Against Children and PLHALead Author: S. Ghosh – IHAA

Community Support to PLWA The experience of Etre Comme Les Autres (ECLA) in Burkina Faso Lead Author: M. Bologo – IHAA

Through its Global Care Initiatives – Step Forward, Tanzania Care, Determine®

HIV Testing Donation Program and Abbott Access – Abbott Laboratories and the

Abbott Laboratories Fund work closely with governments, nongovernmental

organizations (NGOs) and industry partners to create programs to fight AIDS in

the developing world. In collaboration with Axios Foundation, Baylor College of

Medicine, the International HIV/AIDS Alliance, and the governments of Tanzania

and Burkina Faso, Abbott is pleased to present this overview of oral sessions,

poster presentations, CD-ROM abstracts and satellite sessions at the

XV International AIDS Conference.

www.abbottglobalcare.org

Contact Info

Reeta Roy, Divisional Vice PresidentGlobal Citizenship and Policy100 Abbott Park Road, Bldg. AP6D-2, Dept. 383Abbott Park, IL 60064Office: 847.936.0645 • Fax: [email protected]

Jeff Richardson, Executive DirectorStep Forward and Tanzania Care Programs1801 K Street, NW 10th FloorWashington, D.C. 20006Office: 202.530.4741 • Fax: 202.530.4744jeff.richardson@abbottfund.orgwww.stepforwardforchildren.orgwww.tanzaniacare.org

Rob Dintruff, Executive DirectorAccess to HIV Care and PMTCT Donations Programs200 Abbott Park Road, Bldg. AP34-3, Dept. O6MQAbbott Park, Illinois 60064Office: 847.938.7945 • Fax: 847.938.8497rob.dintruff@abbott.comwww.accesstohivcare.orgwww.pmtctdonations.org

Satellite Sessions

The Need to KnowAccelerating Access to TestingGlobal Business CouncilLocation: Royal Orchid Sheraton Saturday, July 10, 2004 2-6PM

From Hope to Reality A summit on the U.S. President’s Emergency Plan for AIDS Relief Global Health CouncilLocation: Room B Exhibition Hall Sunday, July 11, 2004 1:30-6:30PM

Combating Stigma and DiscriminationThe Role of Religious Leaders in Building Inclusive CommunitiesWorld Conference of Religions for Peace Ecumenical Advocacy Alliance, UNAIDLocation: Conference Hall KMonday, July 12, 2004 8:15-10:15PM

State-of-the-Art Management of ARVsAn Interactive Electronic Session AxiosLocation: Room C Exhibition HallTuesday, July 13, 2004 6-8PM

From Policy to ImplementationLeveraging the Power of Industry Global Business Council Location: Room G Exhibition Hall Wednesday, July 14, 2004 12-2PM

Overview of Sessions and Presentations for Abbott Global Care Initiatives and Key Partners

In Collaboration With

XV International AIDS Conference Bangkok, Thailand; July 11-16, 2004

��

Texas Medical Center, Houston, Texas

A Photo Exhibit by Children

Picturing Hope is a project that helps orphans and vulnerable children impacted by HIV/AIDS share their hopes and dreams through photography. The photos were taken by children from Burkina Faso, India, Mexico, Romania and Tanzania and can be seen at Booth 21 in the main Exhibit Hall. Step Forward underwrote this program.

For the 2 million Tanzanians

estimated to be living with

HIV/AIDS, access to basic health

services, counseling and

treatment is nearly unattainable

due to a shortage of specialized

staff, inadequate infrastructure and

facilities, and scarce resources.

Consequently, HIV/AIDS continues

to hinder Tanzanian communities

to an alarming degree.

For more information contact:

Jeff Richardson, Executive DirectorTanzania Care1801 K St., N.W.10th FloorWashington, DC 20006Office: 202.530.4741 • Fax: 202.530.4744 Cell: [email protected]

©2004, Abbott Laboratories, printed in USA Printed on Recycled Paper

Tanzania Care is a partnership among Abbott

Laboratories, the Abbott Laboratories Fund

and the government of Tanzania to modernize the

country’s public health care facilities and

systems, and improve services and access to

care for people living with HIV/AIDS and other

serious illnesses.

28

28 th Annual Dinner & Awards Presentation

th Annual Dinner & Awards Presentation

Dr. Walter A. Orenstein

Sponsored in part by an unrestricted grant from sanofi pasteur

Dr. Orenstein is director of Emory University’s Program for Vaccine Policy and Development and associate director of the Emory Vaccine Center. He received his bachelor’s degree at The City College of New

York and his medical degree from the Albert Einstein College of Medicine. He completed an internship and a residency in pediatrics at the University of California, San Francisco, followed by a fellowship in infectious diseases at the University of Southern California Medical School and a residency in preventive medicine at the U.S. Centers for Disease Control and Prevention (CDC).

Dr. Orenstein has devoted his career to worldwide immunization against infectious diseases. Prior to joining Emory in March 2004, he had a 26-year career at the CDC. He was director of the agency’s National Immunization Program, where he led successful efforts combating the occurrence of once-common childhood diseases, protecting adults from vaccine-preventable diseases, expanding vaccine safety efforts and promoting the use of immunization registries.

Major policies adopted during his tenure include recommendations for a second dose of measles, mumps, rubella vaccine for all children; universal vaccination of children against Haemophilus influenzae type b, hepatitis B, varicella and invasive pneumococcal disease; and annual influenza vaccination of all 50-64 year-old adults and 6-23 month-old children. He served as the agency’s liaison member to the National Vaccine Advisory Committee and the American Academy of Pediatrics Committee on Infectious Diseases.

Dr. Orenstein has served as an Assistant Surgeon General of the U. S. Public Health Service and currently is chairman of the World Health Organization’s Technical Consultative Group on the Global Eradication of Poliomyelitis. In addition, he has been a consultant to the Pan American Health Organization.

Dr. Orenstein is a member of the International Editorial Board for the journal Vaccine. Along with Dr. Stanley Plotkin, he co-edits “Vaccines, 4th edition,” the definitive textbook in the field. He is a fellow of the American Academy of Pediatrics, Infectious Diseases Society of America and Pediatric Infectious Diseases Society. He has served on the Council of the Pediatric Infectious Diseases Society, chaired its Publications Committee and is the outgoing Secretary-Treasurer.

Monday, May 1, 2006The Palace hoTel

San FranciSco, ca

Protect. Learn. Understand. Safeguard.Educating older adults about in�uenza and preventionFrom the National Council on Aging and Sano� Pasteur

To Learn MoreFlu + You is a program of the National Council on Aging in collaboration with Sanofi Pasteur to educate older adults about the seriousness of influenza, the importance of vaccination, and available vaccine options for older adults.

Talk to your health care provider today about your risk for influenza and the vaccination options that might be right for you.

Visit www.ncoa.org/Flu.Vaccination Options for Adults 65 and OlderAs we age, the body’s ability to fight disease declines due to a weakening of the immune system, which results in the body producing fewer antibodies to help fight infection from the flu virus.

Recent studies have shown that the traditional flu vaccine might not work as well for people 65 years of age and older as it does for younger people. The age-related decline in the immune system affects the body’s response to vaccination.

Adults 65 and older have two vaccine options available —the traditional flu shot and a higher dose flu vaccine. The higher dose vaccine is designed specifically for this population to address the age-related decline of the immune system by triggering the body to produce more antibodies against the flu virus than would be produced by the traditional flu shot.

Both vaccine options are covered by Medicare Part B with no copay.

To learn more, visit www.ncoa.org/Flu.

Protect. Learn. Understand. Safeguard.Educating older adults about in�uenza and preventionFrom the National Council on Aging and Sano� Pasteur

COM 10642

Join us for 15 minutes of fame...

Bio 2006

... and a few hours of conversation and fun

Continuing Education (CE)Children with Asthma and Influenza:Practice Models for Improving Influenza Immunization Rates Among Children with Asthma

Program OverviewAsthma is the most common chronic medical condition among children, affecting more than six million chil-dren younger than 18 years of age in the U.S.

Despite longstanding recommenda-tions by the CDC, influenza vaccina-tion rates among children with asthma remain seriously low. Children with chronic medical conditions, includ-ing asthma, are at an increased risk for influenza-related complications (e.g., pneumonia, increased outpatient vis-its and antibiotic prescriptions).

Highlights will be scientific data dem-onstrating the impact of influenza in children with asthma. This program will also focus on practical methods PNPs can employ to increase influ-enza immunization rates among the pediatric population they serve.

Providers agree on the severity of in-fluenza among children with asthma. However, most practices do not have an infrastructure in place to help identify, recall and annually immu-nize these children.

This CE program will feature several strategies and models implemented in a variety of practice settings that have been successful in maximizing pedi-atric asthma influenza immunization rates. It is designed to help PNPs, NPs and nurses have a significant positive impact on influenza vaccination rates among their pediatric patients, partic-ularly for those with chronic medical conditions such as asthma.

Coo

ney/

Wat

ers G

roup

141

Fifth

Ave

, 9th

Flo

orN

ew Y

ork,

NY

1001

0

An

invi

tati

on to

aN

AP

NA

P c

onta

ct h

our

sate

llite

sym

posi

um

Reg

iste

r Now

! e-m

ail:

rsvp

@as

thm

aflu.

com

212-

886-

2265

Acc

redi

tati

on S

tate

men

t: S

anofi

pas

teur

has

bee

n gi

ven

mee

ting

spac

e to

pro

vide

an

educ

atio

nal o

fferin

g du

ring

NA

PN

AP

’s A

nnua

l Con

fere

nce.

NA

PN

AP

’s a

ppro

val o

f mee

ting

spac

e or

con

tinui

ng e

duca

tion

cred

it do

es n

ot im

ply

prod

uct e

ndor

sem

ent.

CHILDREN WITH ASTHMA AND INFLUENZAPractice Models for Improving Influenza Immunization Rates Among Children with Asthma

This program has been approved for 2.4 NAPNAP contact hours of which 1.2 are pharmacology content.

You are invited to attend a NAPNAP contact hour satellite symposium

8


> Monographs/Reports

Making Adult Vaccinations Routine to Reduce Preventable Death and Disability

A Call to Action

from the National Foundation for Infectious Diseasesand the Infectious Diseases Society of America

Strategies for Success

Case Studies in Enhancing Adult and Adolescent Immunization

ImmunizationBest Practicesfor Public Health ProfessionalsImmunization Best Practices

for Public Health Professionals

MKT14287 Best Practices.indd 1 7/8/08 10:21:16 AM

Supported by an unrestricted educational grant to the National Foundation for Infectious Diseases from sanofi pasteur

Identifying and Overcoming Barriers to Improved Influenza Immunization Rates in this High-risk Population

Influenza and Children with Asthma

Call to Action

> Sample of Covers

Keys to Successful Management of Allergy Patients:Focus on Consumer Confidence, Compliance and Satisfaction

A closed-door roundtable convened by the American Academy of Otolaryngic AllergyJanuary 6, 2006, Westin O’HareRosemont, Illinois

COMPLIANCEALLERGIES

9


> Monographs/Reports Layout

National Data Show Immunization Gaps for All VaccinesIn 2008, the CDC reported second-year results from

the National Immunization Survey-Teen (NIS-Teen). This

national survey assesses adolescent vaccination rates

based on data gathered from health care providers.4

None of the vaccines in the survey had coverage rates

of 90 percent, the goal established by “Healthy People

2010,” the Department of Health and Human Services’

national preventive health care initiative (Figure 1).5

Rates were higher for the catch-up vaccines, likely

because they have been on the immunization schedule

for a longer time, and lower for the newer vaccines.

U.S. Adolescents Are Vulnerable to Vaccine-Preventable Diseases Vaccines recommended for adolescents are underused,

leaving our nation’s teens vulnerable to serious morbid-

ity and even death. Health care providers should make

every effort to vaccinate adolescents according to our

national immunization schedule to benefit adolescents,

their close contacts and society at large.* The U.S.

immunization schedule is the product of careful and

extensive review of all aspects of vaccines (e.g., effec-

tiveness, safety, cost) by a 15-member expert panel, the

Advisory Committee on Immunization Practices (ACIP),

and the adoption of the committee’s recommenda-

tions by the Centers for Disease Control and Prevention

(CDC) in collaboration with the American Academy of

Pediatrics, the American Academy of Family Physicians

and other professional organizations.1

Vaccines recommended for use in adolescents can be

grouped into several categories (Table 1).2 Influenza vac-

cine is recommended every year for all children, including

adolescents, up to age 18. Three more recently licensed

vaccines are recommended for first-time administration

during adolescence. “Catch-up” vaccines, which have

been available for a longer time, are for administration to

adolescents who were not immunized or were under-

immunized as infants and toddlers. There are also three

vaccines recommended for use in certain high-risk ado-

lescent subpopulations. Together, these vaccines protect

adolescents from 14 infectious diseases.

Achieving and maintaining high immunization rates is

critical for disease prevention. The highly effective U.S.

childhood immunization program has led to elimination

of smallpox, greater than 99 percent reductions in diph-

theria, measles, polio and rubella, and to a greater than

90 percent reduction in mumps, tetanus and pertussis.3

These successes are rooted in widespread infant and

toddler vaccination. Widespread immunization of ado-

lescents can lead to similar positive results.

However, it is encouraging to note that rates for all vac-

cines increased compared with data from the first NIS-

teen report in 2007. Of the vaccines on the schedule for

at least five years, MMR vaccine coverage is highest at

89 percent and tetanus-containing vaccine coverage

is lowest at 72 percent. The latter is a combined rate

that includes vaccination with either the older tetanus

and diphtheria vaccine (42 percent) or with the newer

Tdap vaccine (30 percent), which includes acellular

pertussis. Inclusion of pertussis is particularly impor-

tant because pertussis has been on the rise in the U.S.

since 1976.6

Vaccines Prevent Serious Morbidity and MortalityVaccine-preventable diseases can cause serious

morbidity and mortality in adolescents and their close

contacts. Even when treated quickly and appropriately,

meningococcal disease kills about 10 to 14 percent

of people infected, and 11 to 19 percent of survivors

suffer serious long-term effects such as hearing loss,

brain damage and digit or limb amputation.7-9 About

70 percent of cases of meningococcal disease in U.S.

adolescents are caused by strains included in the vac-

cine.10 Vaccinating adolescents at 11-12 years of age is

important because adolescents are at increased risk of

meningococcal disease.11

Pertussis is substantially underreported, making it

difficult to pinpoint U.S. incidence,12 but some estimates

range from 1 million to over 3 million cases per year.13,14

Whether cases in adolescents are subclinical, of minor

clinical importance or more severe, infected adoles-

cents may serve as an important reservoir of infection

for neonates and others at higher risk of serious illness

or pertussis-related death.15-18 Tdap is a highly effective

vaccine that replaces the previously recommended Td

vaccine as the booster at 11-12 years of age or in older

adolescents who need a Td booster.2

There are over 6 million new human papillomavirus

(HPV) infections in the U.S. each year; nearly three in

four are in females 15-24 years of age.19 While most of

these infections will be cleared by the immune system,

infection can lead to cervical cancer. The three-dose

HPV vaccine series provides protection against genital

warts and two HPV types (16 and 18) that cause about

70 percent of cervical cancers.20

Catch-up vaccines are more widely used, leading to substantial disease preventionThe catch-up vaccines are associated with much higher

vaccination rates and, therefore, with much greater ben-

efits to date. For example, from 1990 to 2004, incidence

of acute hepatitis B declined 75 percent as infant

immunization increased;21 the last indigenous case of

polio reported in the U.S. was in 1979;22 and, since the

introduction of vaccines to combat measles, mumps and rubella, U.S. incidence of these illnesses has

decreased 99 percent.23

Adolescent Vaccination

2 3 4

Bridging from a strong childhood foundation to a healthy adulthood

Influenza vaccine recommendations expanded to include all adolescentsIn 2008, CDC expanded its influenza recommendations

to include annual immunization of all children 6 months

to 18 years of age.24

Influenza kills more

Americans every year

than all other vaccine-

preventable diseases

combined.25 While

deaths in children are

not common, they do

occur in children of all

ages and health status.

In the 2003-2004

season, 37 percent

of the 153 pediatric

deaths reported were

in children 5 to 18 years of age and 67 percent were in

children with no underlying risk factor26

A Broad Approach Is Necessary to Increase Vaccination RatesBarriers to increased immunization* rates can be

grouped into three main categories: family- or patient-

related, provider-related and system-related. All three

need to be addressed if immunization rates in adoles-

cents are to be increased.

One of the most important issues facing adolescents

is less than optimal use of medical homes and lack of

regular well-care visits. Most primary care visits for ado-

lescents are not preventive visits.27 Therefore, a compre-

hensive health care visit is recommended for all adoles-

cents at 11-12 years of age.28 Making this visit routine for

all adolescents would provide an opportunity to deliver

much needed preventive health services, including

vaccines. However, the absence of such a routine visit

should not deter health care providers from using all

other opportunities (e.g., visits for illness or injury, sports

physicals) to provide vaccines or education and counsel

about the importance of immunization. The end-of-high-

school/college entry point is also a great time to review

immunization status and provide necessary vaccines

before insurance coverage changes.

Changing behavior among adolescents and their parents

or guardians will require education and outreach. While

younger children have little or no control over health care

decisions, adolescents often play a key role in decision

making. Therefore, it is important that adolescents, as

well as their parents or guardians, are educated about

the value of vaccines and the seriousness of vaccine-

preventable diseases. Once empowered, adolescents

and their parents or guardians may generate discussion

with their health care providers about vaccines and other

preventive health measures.

Health care providers must prepare if they are to meet

increased demand for immunization against vaccine-

preventable diseases in adolescents. They can establish

standing orders for vaccination services, use existing

immunization information systems, develop vaccina-

tion “quick visits,” especially for multiple dose vaccines,

establish office guidelines for vaccine delivery, imple-

ment reminder and recall systems, create immuniza-

tion teams (or an immunization leader in the practice)

whose job is to focus on this issue, and use the CDC’s

Comprehensive Clinic Assessment Software Applica-

tion (CoCASA†) to assess office immunization practices.

Health care providers also need to educate themselves

and their colleagues about vaccines and the diseases

they prevent.

However, even if every traditional vaccinator in the coun-

try were perfectly prepared, delivery of all recommended

vaccine doses to adolescents would remain a challenge.

Vaccinations administered at alternative sites, like schools

and pharmacies, may be an integral component of opti-

mal immunization efforts.

System-related vaccination barriers are not remedied

easily by the action of individual health care providers or

the public. However, supportive efforts to minimize such

barriers (e.g., a nationwide immunization tracking system

and a vaccine financing system that allows adolescents

to receive all necessary vaccines, without cost barriers, at

their medical home location) may be instituted.

Source: CDC. MMWR. 2008;57(40):1100-1103.4

*Coverage among teens without a reported history of disease.†HPV rates among adolescent females only.Hep=hepatitis; Men=meningococcal disease; NA=not available; Tet=tetanus–containing vaccine; Var=varicella.

Hep B(≥3)

MMR (≥2)

Tet(≥1)

HPV† Var*(≥1)

Men(1)

Percent Immunized

0

20

40

60

80

100

89 88

7672

3225

30Tdap

42Td

Vaccine (No. of Doses)

Figure 1

Vaccination Rates in Adolescents 13-17 Years of Age, U.S.—2007

†Information about CoCASA is available at http://www.cdc.gov/vaccines/pro-grams/cocasa/default.htm.

*NFID refers readers interested in this topic to the following publication, released as this Call to Action was being completed: Strengthening the Delivery of New Vaccines for Adolescents. Pediatrics; 2008 Jan;121(Supplement 1).

*A CME-accredited monograph, Roadmaps for Clinical Practice: Improving Adolescent Immunizations–A Primer for Physicians, is available from the American Medical Association at http://www.ama-assn.org/ama/pub/category/6886.html.

Table 1

Vaccines for Adolescents*

Vaccines for routine administration to all Adolescents†

n Influenza (1 dose annually)

n Human papillomavirus (3-dose primary series)

n Meningococcal conjugate vaccine (1 primary dose)

n Tetanus, diphtheria and acellular pertussis (1

booster dose)

Catch-up vaccines for adolescents not fully immunized previously

n Hepatitis B

n Inactivated polio

n Measles, mumps and rubella

n Varicella‡

Vaccines for certain high-risk adolescentsn Hepatitis A

n Pneumococcal polysaccharide

*See MMWR for each vaccine for detailed information.† Influenza vaccination needed annually, all other recommended at 11-12 years of age.

‡ As of 2006, two doses are recommended (at 12-15 months and 4-6 years). Adolescents who received one dose should have a catch-up dose.

Source: CDC. MMWR. 2008;57(01):Q1-Q4.2

This publication made possible by an unrestricted educational grant to the

National Foundation for Infectious Diseases by sanofi pasteur.

Editorial Board

William Schaffner, MD, Chairman

Dennis A. Brooks, MD, MPH, MBA

Hal B. Jenson, MD

Linda Juszczak, DNSc, MPH, CPNP

Bonnie M. Word, MD

Adolescent Vaccination

Bridging from a Strong Childhood Foundation to a Healthy Adulthood

A report on strategies to increase

adolescent immunization rates

10

Educating About Adolescent Meningitis PreventionA National Meningitis Association Program

Parent Teacher Awareness

theShots A Meningococcal Disease Awareness Program

Targeting Adolescents and Young Adults

Calling

A VNAA program supported by sanofi pasteur


> Logos




Unpublished Logo Comp for Lupus Awareness Campaign

Listen to Epilepsy AdvocateTM



EpilepsyAdocate.comVisit


EpilepsyAdocate.com EpilepsyAdocate.com

become our fan on facebook

become our fan on facebookbecome our fan

on facebook


Logo for National NCOA Awareness Initiative

Vaccinology

A Short Course on How Vaccines Work And How They Might Work for You


Almost Everything You EverWanted to Know About


Vaccinology A Short Course on How Vaccines Work And How They Might Work for You


Vaccinology



Vaccinology



Vaccinology





Vaccinology

11


> Collateral Materials for Abbott Fund

Health at Home/Kenya—A GBC Impact Initiative to Fight AIDS, TB and Malaria

GBC

GLOBAL BUSINESS COALITIONON HIV/AIDS,TUBERCULOSIS AND MALARIA

AFFORDABLE QUALITY HEALTH CARE

GBC

GLOBAL BUSINESS COALITIONON HIV/AIDS,TUBERCULOSIS AND MALARIA

Health at Home | Kenya

Home-based Counseling and Testing – HCT for 2 Million People in Western Kenya

A GBC Impact Initiative

United Republic of Tanzania

Ministry of Healthand Social Welfare

Abbott Fund is working with partners on the ground to improve the health of communities around the world.

To learn more, visit: www.abbottfund.org

Healthy People, Stronger Communities

This young Cambodian girl and her mother receive health care education and other services from Abbott Fund-supported Angkor Hospital for Children.

An initiative of CUH2A

Mt. Meru Hospital regional laboratory modernized by Abbott Fund in 2007

State of many health laboratories in Tanzania

MOHSWn Leadership, coordination and

oversight of project n Commitment to scaling-up

HIV/AIDS response in Tanzania

n Nationwide laboratory needs assessment

n Existing partnerships with CDC and Abbott Fund

Abbott Fund Tanzanian Funding for National

Laboratory Modernization Project

n Experience in project management

n Experience in laboratory improvements in Tanzania

n Commitment to support MOHSW in Tanzania

D4On Expertise in laboratory

designn Experience in

project planning and implementation

CDC-Tanzanian Scientific expertisen Coordination of partners’

contributions and liaison between partners, Tanzania PEPFAR team and USG headquarters offices

APHL n Collaborative partnershipn Expertise in public health

laboratory management and operations

n Experience in Tanzania laboratory system

Implementing Partners

Public-Private Partnership

We would like to invite you to join us for a reception to celebrate the opening of our new Abbott Fund

office in Dar es Salaam and the opportunity to meet with

Abbott Chairman and CEO, Miles D. White

June 27, 2007 6:00-7:30 P.M.Abbott Fund Offices | 17th Floor, PPF Towers

Corner of Garden and Ohio, Dar es Salaam

RSVP: �� : �� : �� : ��

To learn more, visit: www.abbott.com/haiti

Photo: Brett Williams/Direct Relief International

Abbott and the Abbott Fund are working directly with trusted partner organizations to assess and respond to immediate health needs as well as longer-term recovery and rebuilding efforts in Haiti. We salute our partners, other humanitarian aid organizations and the people of Haiti who are working tirelessly to help rebuild the country.

Honoring Our Partners Who Are Helping Rebuild Haiti

To learn more, visit: www.abbottfund.org

Using Innovative Programs to Combat NCDs and Improve Health

Abbott and the Abbott Fund are working with partners on the ground, in Kenya, Bolivia and beyond to leverage innovative solutions to improve health outcomes.

Patient John’s story is representative of the struggle so many patients face on a daily basis. John is employed as a driver, transporting many life-saving supplies and Health Counselors needed for providing HIV care, for the Academic Model Providing Access to Healthcare (AMPATH). His recent diagnosis of diabetes had threatened his very livelihood as the insidious complications of diabetes were starting to set in and prevent him from performing his job responsibilities. With just four months of care, John became symptom free and is back to his regular duties as one of AMPATH’s drivers. AMPATH is providing comprehensive diabetes care services in rural areas of western Kenya where none had previously existed and now cares for more than 2,000 diabetic patients. AMPATH integrates chronic disease care for the approx. 300,000 patients who receive HIV/AIDS, prenatal, and primary care services in its clinics.

Señora Montaño has had diabetes all her life, is blind in both eyes and often needed hospitalization. She lives in Cochabamba, Bolivia’s third-largest city, where more than 9 percent of the population suffers from diabetes—Clinica Vivir con Diabetes (CVCD), Abbott Fund and Direct Relief International’s local partner, diagnoses and treats patients with diabetes throughout the city. CVCD is the region’s only diabetes clinic, delivering care at little or no cost to patients like Señora Montaño. CVCD sends trained social workers to visit diabetes patients at home to ensure that they know how to manage their condition. Señora Montaño got a cane and plans to go to the clinic in the future. Over the past five years, CVCD has served more than 66,000 diabetes patients, counseling them on disease management techniques and healthy living habits. CVCD’s annual rate of detection of diabetes has also increased by 250 percent.

portfolio 1 16 james winslow

Documents